Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter.

Recent studies reported negative predictors for immune checkpoint inhibitors (ICI) in non–small cell lung cancer (NSCLC), including STK11, KEAP1 , and PTEN ([1–3][1]). Aggarwal and colleagues' study showed that patients with NSCLC with high blood-based tumor mutation burden (bTMB) and absence of